EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A new era in myeloma: the advent of chimeric antigen receptor‐T (CAR‐T) cells and bispecific antibodies

P Joy Ho iD, Eric W Li

Internal Medicine Journal · 2025

DOI: 10.1111/imj.16647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von P Joy Ho und 1 weiteren Autor:innen. Beteiligte Einrichtung: Royal Prince Alfred Hospital, Institute of Haematology, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Immunotherapy, Adoptive, Multiple Myeloma, Receptors, Chimeric Antigen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T‐cell re‐directional therapies, including chimeric antigen receptor (CAR)‐T cell and bispecific antibodies (BsA), have transformed the treatment landscape to benefit patients with multiple myeloma. A number of these novel therapies has been approved internationally, with CAR‐T therapy recently approved in Australia. In this clinical perspective, we describe the development of CAR‐T and BsA therapies, highlighting the clinical benefits and risks, together with the significant costs and infrastructure support required for the provision of these therapies to myeloma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificImmunotherapy, AdoptiveMultiple MyelomaReceptors, Chimeric AntigenHumansAustralia

Stichwörter der Autor:innen

bispecific antibodycellular therapychimeric antigen receptor‐T therapyimmunotherapymultiple myeloma

Substanzen

Antibodies, BispecificReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Royal Prince Alfred Hospital, Institute of Haematology, Sydney, New South Wales, Australia.
  • Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: P Joy Ho

Zitieren

APA

Ho, P. J., & Li, E. W. (2025). A new era in myeloma: the advent of chimeric antigen receptor‐T (CAR‐T) cells and bispecific antibodies. Internal Medicine Journal. https://doi.org/10.1111/imj.16647

Vancouver

Ho PJ, Li EW. A new era in myeloma: the advent of chimeric antigen receptor‐T (CAR‐T) cells and bispecific antibodies. Internal Medicine Journal. 2025. doi:10.1111/imj.16647

BibTeX
@article{Ho2025,
  author = {Ho, P Joy and Li, Eric W},
  title = {A new era in myeloma: the advent of chimeric antigen receptor‐T (CAR‐T) cells and bispecific antibodies},
  journal = {Internal Medicine Journal},
  year = {2025},
  doi = {10.1111/imj.16647}
}
Kostenlos starten →